HT
AKBA icon

Headlands Technologies’s Akebia Therapeutics AKBA Stock Holding History

Headlands Technologies’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.9K Buy
77,992
+29,334
+60% +$34.9K 0.01% 665
2026
Q1 		$67.6K Buy
+48,658
New +$66.9K 0.01% 686
2025
Q3 		– Sell
-1,254
Closed -$4.57K – 618
2025
Q2 		$4.57K Buy
+1,254
New +$3.45K ﹤0.01% 1071
2024
Q3 		– Sell
-208
Closed -$212 – 1162
2024
Q2 		$212 Sell
208
-2,529
-92% -$3.13K ﹤0.01% 1079
2024
Q1 		$5.01K Buy
+2,737
New +$4.38K ﹤0.01% 1102

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Headlands Technologies's AKBA Position: Q2 2026 in Review

Headlands Technologies increased its Akebia Therapeutics (AKBA) stake by 60% in Q2 2026, buying an estimated $34.9K and bringing the position to 77,992 shares worth $88.9K. The position accounts for 0.01% of the portfolio, ranked #665.

Headlands Technologies first reported a position in AKBA in Q1 2024 and has held it in 5 quarters since. 170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Headlands Technologies held 77,992 shares of Akebia Therapeutics worth $88.9K as of Q2 2026.
  • Headlands Technologies bought 29,334 Akebia Therapeutics shares in Q2 2026, an estimated $34.9K.
  • Akebia Therapeutics made up 0.01% of Headlands Technologies's portfolio in Q2 2026, its #665 holding.
  • Headlands Technologies first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.